Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Myelodysplastic Syndromes 42Leukemia, Lymphocytic, Chronic, B-Cell 40Leukemia 38Lymphoma, Non-Hodgkin 32Multiple Myeloma 31Lymphoma 31Lymphoma, Mantle-Cell 26Lymphoma, Follicular 24Lymphoma, Large B-Cell, Diffuse 23Hodgkin Disease 22Melanoma 21Burkitt Lymphoma 19Lymphoma, B-Cell, Marginal Zone 18Leukemia, Myelomonocytic, Chronic 17Recurrence 14Anemia, Refractory, with Excess of Blasts 14Congenital Abnormalities 13Neoplasms, Plasma Cell 12Myeloproliferative Disorders 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large-Cell, Immunoblastic 11Hematologic Neoplasms 11Leukemia, Myeloid, Chronic-Phase 10Primary Myelofibrosis 9Lymphoma, Large-Cell, Anaplastic 9Lymphoma, B-Cell 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Ovarian Neoplasms 8

Interventions

Cyclophosphamide 2fludarabine phosphate 1fludarabine 1Vincristine 1Prednisone 1Interleukin-2 1Inotuzumab Ozogamicin 1Etoposide 1Doxorubicin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × fludarabine phosphate × Clear all
NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

Fate Therapeutics

Phase 1 Active not recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡